Radx tech 2375 - point of need, saliva-based, covid-19 testing platforms
Ended Definitive Contract Awarded Last action
- Contract number
- 75N92021C00018
- Awardee
-
Flambeau Diagnostics LLC UEI VLZHU9Z7URH3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $16,670,000
Award facts
- Contract value 74% obligated
-
- $16,670,000.00 Current, with exercised options
- $22,570,000.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Madison, WI 53716, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Close Out | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Definitize Letter Contract | $12,970,000 | |
| Other Administrative Action | $0 | |
| Original award | $3,700,000 |
About this award
Flambeau Diagnostics LLC was awarded a definitive firm fixed-price contract valued at $22.57 million by the National Heart, Lung, and Blood Institute (NHLBI) on July 1, 2021, for the development of point-of-need, saliva-based COVID-19 testing platforms under the RADX Tech 2375 program. The contract was performed in Madison, Wisconsin, with an ultimate completion date of March 31, 2023. This award did not utilize a set-aside designation and represents a civilian agency procurement for critical pandemic response infrastructure.
The RADX Tech initiative, supported by the NHLBI, aimed to accelerate the development and implementation of rapid, point-of-care diagnostic testing solutions to expand COVID-19 testing capacity throughout the United States. By focusing on saliva-based testing platforms, this contract sought to enable more accessible, less invasive diagnostic options that could be deployed rapidly across diverse settings. Flambeau Diagnostics' deliverables under this program contributed to the federal government's broader effort to enhance pandemic response capabilities through innovative diagnostic technologies during the height of the COVID-19 pandemic response.
Quick answers
Who was awarded contract 75N92021C00018?
75N92021C00018 was awarded to Flambeau Diagnostics LLC by National Heart Lung and Blood Institute (National Institutes of Health) on July 1, 2021.
How much is contract 75N92021C00018 worth?
The government has obligated $16,670,000 on 75N92021C00018. Its potential value, with all options, is $22,570,000.
Was contract 75N92021C00018 competed?
The extent of competition for 75N92021C00018 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award